
Marc Frappier
Eurazeo - President
With 11 members, the Supervisory board is responsible for supervising and controlling the activity of the management board and the CEO. The Supervisory Board has implemented 3 specific committees.
Marc Frappier
Eurazeo - President
Supervisory board
Edouard Guigou
Eurazeo
Sophie Flak
Eurazeo
Cécile Gilliet
Eurazeo
Lorine Bayon
Eurazeo
Wilfried Piskula
Eurazeo
Frédéric Collard
Ardian
Daniele Cardoso
Independent member
Gilles Aufret
Independent member
Thierry Chignon
Mérieux Development
Margalit Fine
Independent member
The Executive Committee comprises 14 members and is chaired by Pierre Luzeau. Its mission is to steer the strategic roadmap defined with the Supervisory Board to meet the group’s improvement and development objectives.
Pierre Luzeau
Seqens - Chief Executive Officer
Executive committee
Vincent Milhau
Seqens - Chief Financial Officer
Jean-Louis Martin
Seqens - VP HR & Industrial
Vanessa Michoud
Seqens - General Counsel
Laurent Castor
Seqens - VP Specialty Ingredients
Philippe Clavel
SEQENS - VP Pharmaceutical solutions
Raymond Sinnah
Seqens - VP Mineral Specialties & ExCo supervisor Asia
Christophe Eychenne-Baron
Seqens - Group R&D Director
Stéphanie Girard
Seqens - Quality and Regulatory Affairs Director
Robert Monti
Seqens - Essential Drug Substances DS Managing Director
Sébastien Taillemite
Seqens - Advanced Specialties Managing Director
Helen Webster
Seqens - Custom Specialties Managing Director
Gildas Barreyre
Seqens - ExCo General Secretary
Ludovic Lyonnet
Seqens - SPS Business Director
Developing and protecting Seqens’ strategy, values and assets: its missions include formulating and implementing the group’s strategic vision and objectives. The ExCo also steers the group’s business portfolio and is responsible for fulfilling the group’s objectives of creating value.
Managing performance: within his/her scope, each ExCo member manages the performance of business units or function leaders, allocating group-wide resources and governing the group’s activities.